Cisplatin Encapsulated Plasmonic Blackbodies for NIR Light Activatable Chemo‐Phototherapy and Reduction of 4‐Nitrophenol

Abstract

AbstractCisplatin (CDDP) is an FDA‐approved chemotherapeutic drug used for treating various solid tumors. Despite of its effectiveness towards chemotherapy, it faces several challenges, such as multi‐drug resistance (MDR) and significant damage to the normal tissues. To address these challenges, various nanoformulations were developed to improve the delivery and safety of CDDP. One of the limitation in these CDDP loaded nanoformulations is that the effective CDDP loading concentrations are very poor. Therefore, this leaves a grand challenge to develop an effective strategy to carry higher concentrations of CDDP molecules, and also simultaneously exhibit very unique properties. Herein, we have developed an one‐pot synthesis of Cisplatin encapsulated Plasmonic blackbody (CiP), which offers a double play for near infrared (NIR) light activatable chemo‐photothermal therapy in destructing cancer cells as well as mediate catalytic reduction of 4‐nitrophenol (4‐NP). The CiP nanoformulation exhibits superior light absorbing capabilities in the NIR region with an appreciable photothermal conversion efficiency of 41 %. Further, NIR light activatable combinatorial therapeutic approach of CiP was demonstrated against ovarian cancer cells and as a catalyst for the reduction of model pollutant 4‐nitrophenol. Our findings highlight the potential of CiP as a versatile platform for light‐activated combinatorial cancer therapy and environmental pollutant remediation.